Skip to main content

Advertisement

Table 1 Patients characteristics

From: Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy

Patient ID# Sex Age (Year)a Site Relapse time (months)b Chemotherapy/Length(months)c Survival
Control patients
 1 M 5 Spinal Cord 27   Alive
 2 M 11 Spinal Cord 30   Deceased
 3 M 2 Cerebellum 31   Alive
 4 M 11/12 Cerebellum 8   Alive
 5 F 4 Left Thalamic 19   Alive
 6 M 16 Left intraventricular 58   Alive
 7 F 13 Right Front Lobe 20   Alive
 8 F 5 Right lateral ventricle subependymal 107   Alive
Investigative patients
 9 M 4 Cerebellum 8 CPL, VIN/12, TPCV/14 Alive
 10 M 3 Left Temporal Lobe 13 CPL/4, VCR/4, VIN/10 Alive
 11 F 4 Right Temporal Lobe 8 CPL/8, VCR/8 Alive
 12 F 7 Spinal Cord 12 CPL/7, VCR/7, ISP/4 Deceased
 13 F 1 Suprasellar/Third ventricle 46 CPL, VCR/4, VIN/9, O6-BG & TMZ/2 Deceased
 14 F 1 C4-T4 spinal cord 27 CPL, VCR, TMZ/12 Alive
 15 M 7/12 Posterior Fossa 10 CPL, ETO, TAM/10 Deceased
  1. aAge at initial diagnosis
  2. bTime of relapse after first operation
  3. cInitial chemotherapy/length of treatment (months) after first operation
  4. Abbreviations: M male, F female, CPL carboplatin, VCR vincristine, VIN vinblastine, TPCV Thioguanine, Procarbazine, CCNU and Vincristine, ISP ispinesib, ETO etoposide, TAM tamoxifen, O 6 -BG O6-Benzylguanine, TMZ temozolomide